Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
ZimetaTM should not be used more frequently than every 12 hours. For use in horses only. Do not use in horses with a hypersensitivity to dipyrone, horses intended for human consumption or any food producing animals, including lactating dairy animals.
First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy
As we begin the final month of 2019, the U.S. Food and Drug Administration has several PDUFA dates to approve drug applications.
Ted W. Love, president and chief executive officer of GBT, called the approval of Oxbryta a major milestone for the company and for patients with sickle cell disease.
Motif Bio plc announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares and listed warrants from the Nasdaq Capital Market.
The collaboration will use Image Processing and Artificial Intelligence/Machine Learning to revolutionise pathology practice and provide more precise cancer diagnostic assays
Promore Pharma AB has prepared a supplementary prospectus to the prospectus regarding the rights issue of approx.
Innovation Pharmaceuticals, a clinical stage pharmaceutical company, is pleased to inform shareholders the Company received notification from the Food and Drug Administration that a waiver has been granted eliminating the need to study Brilacidin, for the prevention of Severe Oral Mucositis in Head and Neck Cancer patients receiving chemoradiation, in pediatric populations.
Shares of specialty pharmacy company Aquestive Therapeutics are up more than 18% in premarket trading following a late Friday afternoon approval from the U.S. FDA for Exservan, a treatment for amyotrophic lateral sclerosis.
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa